Your SlideShare is downloading. ×
Global biopharmaceutical market report (2010 2015)
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Global biopharmaceutical market report (2010 2015)

7,635
views

Published on

Published in: Business

0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
7,635
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
319
Comments
0
Likes
2
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. About IMARC For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
  • 2. © IMARC® Report Description & Highlights The Global Biopharmaceutical Industry has come a long way since its first drug- Humulin was approved in 1982. Today more than three hundred biopharmaceuticals have already been approved and many more are in late stage clinical development. These drugs have not only advanced the prevention and treatment of a number of life threatening diseases, but have also provided the thrust for the continued success of the pharmaceutical industry. Under mounting economic pressures to increase their outputs, pharmaceutical manufacturers have embraced biopharmaceuticals as a means to maintain flow in their drying pipelines. Bringing a biopharmaceutical, however, represents a very risky proposition and out of every ten drugs that enter the clinical phases, only three manage to gain market approval. But the industry’s US$ 92 Billion figures and double digit growth rates in the last five years are a testimonial to the fact that the ones that finally do get approval represent goldmines for investors. Although factors such as biosimilar entry and cost containment in the developed markets are likely to restrain the growth of this market in the coming years, Imarc expects that the high potency and ability of biopharmaceuticals to attack targets beyond the reach of traditional small molecule drugs gives the industry a huge scope for future growth. A rich late stage pipeline and the growth of emerging markets are also expected to be major drivers for growth in the next five years. IMARC expects the global biopharmaceutical market to reach level of sales figures worth more than US$ 167 Billion by 2015. IMARC’s new report “Global Biopharmaceutical Market Report (2010-2015)” gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure, therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2015. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the global biopharmaceutical market in some form or the other. Report Highlights Biopharmaceuticals enjoy a higher approval success rate compared to traditional small molecule drugs. They, however, require higher investments and take longer development times. Biopharmaceuticals are significantly more expensive than traditional medications, with the annual cost of therapy of some biopharmaceuticals touching more than a hundred thousand dollars a year. The cost of these drugs, however, is expected to be closely scrutinized by payers in the coming years.
  • 3. © IMARC® Recombinant Proteins represented the biggest biopharmaceutical class in 2009, accounting for more than 65% of the total global biopharmaceutical sales. Growth in this class is expected to be low in most of the developed markets as a result of biosimilar entry and increasing cost containment measures. Monoclonal Antibodies are expected to be the biggest drivers of the biopharmaceutical market in the next five years. Driven by a rich late stage pipeline and a strong uptake from both developed and emerging market, Monoclonal Antibodies are expected to be worth more than US$ 79 Billion by 2015. Imarc expects the top eight markets (US, Germany, Japan, France, Italy, Spain, UK and Canada) to account for around 79% of the total global biopharmaceutical sales by 2015. This represents a decline of 4% over their 2009 share. The market share of emerging markets (Brazil, Russia, India, China, Mexico, Turkey and South Korea) is likely to increase from less than 5% in 2009 to more than 8% by 2015. Regions/Countries Covered Global, US, Germany, Japan, France, Italy, Spain, United Kingdom, Canada, Russia, China, Australia, Turkey, Mexico, South Korea, India, Brazil, Argentina and Indonesia. Classes Covered for Each Region/Country Recombinant Proteins, Insulin, Erythropoietins, Interferons, Colony Stimulating Factors, Immunoglobulins, Recombinant Blood Factors, Growth Hormones, Recombinant Enzymes, Interleukins, Growth Factors, Monoclonal Antibodies and Purified Proteins. Key Features Analysis of the key strengths, weaknesses, opportunities and threats faced by the global biopharmaceutical market. Exhaustive in-depth individual analysis for eighteen major developed and emerging markets. 2005 to 2009 trend analysis for the global and 18 selected biopharmaceutical markets. 2005 to 2009 trend analysis for individual biopharmaceutical classes for the global and 18 selected biopharmaceutical markets. 2005 to 2009 trend analysis for the performance of top players for the global and 18 selected biopharmaceutical markets. 2010-2015 sales forecast for the global and 18 selected biopharmaceutical markets.
  • 4. © IMARC® Table of Contents 1.  Market Definitions & Research Methodology..............................................................................18  2.  Analyst Briefing..............................................................................................................................21  3.  Introduction to Biopharmaceuticals.............................................................................................26  4.  Global Biopharmaceutical Market: Industry Analysis................................................................29  4.1  Strengths.....................................................................................................................................29  4.1.1  High Efficacy and Target Oriented Attack...........................................................................29  4.1.2  Strong Potential to Achieve Blockbuster Status..................................................................29  4.1.3  Limited Generic Threat........................................................................................................31  4.1.4  Approval Success Rates are Higher than Small Molecule Drugs.......................................34  4.2  Weaknesses ...............................................................................................................................34  4.2.1  Inconvenient Drug Delivery Coupled with Short Half Lives.................................................34  4.2.2  Second Line of Therapy......................................................................................................35  4.2.3  Huge Cost of Therapy.........................................................................................................36  4.2.4  High Incidence of Unfavorable Side Effects........................................................................37  4.3  Opportunities...............................................................................................................................37  4.3.1  Diseases with High Unmet Needs.......................................................................................37  4.3.2  Expanding the Patient Pool by Approval into Additional Indications...................................38  4.3.3  Emerging Markets ...............................................................................................................39  4.3.4  Increasing New Approvals and a Strong Pipeline...............................................................41  4.4  Threats........................................................................................................................................44  4.4.1  Biopharmaceutical Drug Development is a Very Risky Venture.........................................44  4.4.2  Biosimilars...........................................................................................................................45  4.4.3  Limited and Conditional Reimbursement............................................................................47  4.4.4  Uncertainties in the Economic Environment .......................................................................48  5.  Global Biopharmaceutical Market: Industry Performance.........................................................50  5.1  Market Performance & Forecast.................................................................................................50  5.1.1  Current Performance (2005-2009)......................................................................................50  5.1.2  Market Forecasts (2010-2015)............................................................................................50  5.2  Market Segmentation by Region ................................................................................................52  5.2.1  Current Performance (2005-2009)......................................................................................52  5.2.2  Market Forecasts (2010-2015)............................................................................................54  5.3  Market Segmentation by Indication ............................................................................................56  5.4  Market Segmentation by Class...................................................................................................57  5.4.1  Recombinant Proteins.........................................................................................................59  5.4.1.1  Current Performance (2005-2009)..............................................................................59  5.4.1.2  Market Forecasts (2010-2015)....................................................................................61  5.4.2  Monoclonal Antibodies........................................................................................................63  5.4.2.1  Current Performance (2005-2009)..............................................................................63  5.4.2.2  Market Forecast (2010-2015)......................................................................................67  5.4.3  Purified Proteins..................................................................................................................70  5.4.3.1  Current Performance (2005-2009)..............................................................................70  5.4.3.2  Market Forecast (2010-2015)......................................................................................72  5.5  Competitive Landscape ..............................................................................................................73  5.5.1  Top Biopharmaceutical Players ..........................................................................................73  5.5.2  Top Biopharmaceutical Drugs.............................................................................................75  6.  North America.................................................................................................................................77  6.1  US ...............................................................................................................................................77  6.1.1  Market Performance (2005-2009).......................................................................................77 
  • 5. © IMARC® 6.1.2  Market Segmentation by Class ...........................................................................................77  6.1.2.1  Recombinant Proteins.................................................................................................78  6.1.2.2  Monoclonal Antibodies ................................................................................................80  6.1.2.3  Purified Proteins..........................................................................................................82  6.1.3  Performance of Top Players ...............................................................................................83  6.1.4  Market Forecasts (2010-2015)............................................................................................84  6.2  Canada .......................................................................................................................................86  6.2.1  Market Performance (2005-2009).......................................................................................86  6.2.2  Market Segmentation by Class ...........................................................................................86  6.2.2.1  Recombinant Proteins.................................................................................................87  6.2.2.2  Monoclonal Antibodies ................................................................................................89  6.2.3  Performance of Top Players ...............................................................................................91  6.2.4  Market Forecasts (2010-2015)............................................................................................92  7.  Latin America..................................................................................................................................94  7.1  Mexico.........................................................................................................................................94  7.1.1  Market Performance (2005-2009).......................................................................................94  7.1.2  Market Segmentation by Class ...........................................................................................94  7.1.2.1  Recombinant Proteins.................................................................................................95  7.1.2.2  Monoclonal Antibodies ................................................................................................97  7.1.2.3  Purified Proteins..........................................................................................................99  7.1.3  Performance of Top Players ...............................................................................................99  7.1.4  Market Forecasts (2010-2015)..........................................................................................101  7.2  Brazil.........................................................................................................................................102  7.2.1  Market Performance (2005-2009).....................................................................................102  7.2.2  Market Segmentation by Class .........................................................................................102  7.2.2.1  Recombinant Proteins...............................................................................................103  7.2.2.2  Monoclonal Antibodies ..............................................................................................105  7.2.2.3  Purified Proteins........................................................................................................107  7.2.3  Performance of Top Players .............................................................................................108  7.2.4  Market Forecasts (2010-2015)..........................................................................................109  7.3  Argentina...................................................................................................................................111  7.3.1  Market Performance (2005-2009).....................................................................................111  7.3.2  Market Segmentation by Class .........................................................................................111  7.3.2.1  Recombinant Proteins...............................................................................................112  7.3.2.2  Monoclonal Antibodies ..............................................................................................114  7.3.2.3  Purified Proteins........................................................................................................115  7.3.3  Performance of Top Players .............................................................................................116  7.3.4  Market Forecasts (2010-2015)..........................................................................................117  8.  Europe ...........................................................................................................................................119  8.1  Germany ...................................................................................................................................119  8.1.1  Market Performance (2005-2009).....................................................................................119  8.1.2  Market Segmentation by Class .........................................................................................119  8.1.2.1  Recombinant Proteins...............................................................................................120  8.1.2.2  Monoclonal Antibodies ..............................................................................................122  8.1.2.3  Purified Proteins........................................................................................................123  8.1.3  Performance of Top Players .............................................................................................125  8.1.4  Market Forecasts (2010-2015)..........................................................................................126  8.2  France.......................................................................................................................................128  8.2.1  Market Performance (2005-2009).....................................................................................128  8.2.2  Market Segmentation by Class .........................................................................................128  8.2.2.1  Recombinant Proteins...............................................................................................129  8.2.2.2  Monoclonal Antibodies ..............................................................................................131  8.2.2.3  Purified Proteins........................................................................................................133  8.2.3  Performance of Top Players .............................................................................................133  8.2.4  Market Forecasts (2010-2015)..........................................................................................135 
  • 6. © IMARC® 8.3  Italy ...........................................................................................................................................136  8.3.1  Market Performance (2005-2009).....................................................................................136  8.3.2  Market Segmentation by Class .........................................................................................136  8.3.2.1  Recombinant Proteins...............................................................................................137  8.3.2.2  Monoclonal Antibodies ..............................................................................................139  8.3.2.3  Purified Proteins........................................................................................................141  8.3.3  Performance of Top Players .............................................................................................141  8.3.4  Market Forecasts (2010-2015)..........................................................................................143  8.4  Spain.........................................................................................................................................145  8.4.1  Market Performance (2005-2009).....................................................................................145  8.4.2  Market Segmentation by Class .........................................................................................145  8.4.2.1  Recombinant Proteins...............................................................................................146  8.4.2.2  Monoclonal Antibodies ..............................................................................................148  8.4.2.3  Purified Proteins........................................................................................................150  8.4.3  Performance of Top Players .............................................................................................151  8.4.4  Market Forecasts (2010-2015)..........................................................................................152  8.5  UK .............................................................................................................................................154  8.5.1  Market Performance (2005-2009).....................................................................................154  8.5.2  Market Segmentation by Class .........................................................................................154  8.5.2.1  Recombinant Proteins...............................................................................................155  8.5.2.2  Monoclonal Antibodies ..............................................................................................157  8.5.2.3  Purified Proteins........................................................................................................159  8.5.3  Performance of Top Players .............................................................................................160  8.5.4  Market Forecasts (2010-2015)..........................................................................................162  8.6  Russia.......................................................................................................................................163  8.6.1  Market Performance (2005-2009).....................................................................................163  8.6.2  Market Segmentation by Class .........................................................................................163  8.6.2.1  Recombinant Proteins...............................................................................................164  8.6.2.2  Monoclonal Antibodies ..............................................................................................166  8.6.2.3  Purified Proteins........................................................................................................168  8.6.3  Performance of Top Players .............................................................................................170  8.6.4  Market Forecasts (2010-2015)..........................................................................................171  8.7  Turkey.......................................................................................................................................173  8.7.1  Market Performance (2005-2009).....................................................................................173  8.7.2  Market Segmentation by Class .........................................................................................173  8.7.2.1  Recombinant Proteins...............................................................................................174  8.7.2.2  Monoclonal Antibodies ..............................................................................................176  8.7.2.3  Purified Proteins........................................................................................................178  8.7.3  Performance of Top Players .............................................................................................179  8.7.4  Market Forecasts (2010-2015)..........................................................................................180  9.  Asia Pacific ...................................................................................................................................182  9.1  Japan ........................................................................................................................................182  9.1.1  Market Performance (2005-2009).....................................................................................182  9.1.2  Market Segmentation by Class .........................................................................................183  9.1.2.1  Recombinant Proteins...............................................................................................184  9.1.2.2  Monoclonal Antibodies ..............................................................................................186  9.1.2.3  Purified Proteins........................................................................................................188  9.1.3  Performance of Top Players .............................................................................................189  9.1.4  Market Forecasts (2010-2015)..........................................................................................190  9.2  China.........................................................................................................................................192  9.2.1  Market Performance (2005-2009).....................................................................................192  9.2.2  Market Segmentation by Class .........................................................................................192  9.2.2.1  Recombinant Proteins...............................................................................................193  9.2.2.2  Monoclonal Antibodies ..............................................................................................196  9.2.2.3  Purified Proteins........................................................................................................197  9.2.3  Performance of Top Players .............................................................................................199  9.2.4  Market Forecasts (2010-2015)..........................................................................................200 
  • 7. © IMARC® 9.3  Australia....................................................................................................................................202  9.3.1  Market Performance (2005-2009).....................................................................................202  9.3.2  Market Segmentation by Class .........................................................................................202  9.3.2.1  Recombinant Proteins...............................................................................................203  9.3.2.2  Monoclonal Antibodies ..............................................................................................205  9.3.2.3  Purified Proteins........................................................................................................206  9.3.3  Performance of Top Players .............................................................................................207  9.3.4  Market Forecasts (2010-2015)..........................................................................................208  9.4  South Korea..............................................................................................................................210  9.4.1  Market Performance (2005-2009).....................................................................................210  9.4.2  Market Segmentation by Class .........................................................................................210  9.4.2.1  Recombinant Proteins...............................................................................................211  9.4.2.2  Monoclonal Antibodies ..............................................................................................214  9.4.2.3  Purified Proteins........................................................................................................215  9.4.3  Performance of Top Players .............................................................................................216  9.4.4  Market Forecasts (2010-2015)..........................................................................................218  9.5  India ..........................................................................................................................................219  9.5.1  Market Performance (2005-2009).....................................................................................219  9.5.2  Market Segmentation by Class .........................................................................................219  9.5.2.1  Recombinant Proteins...............................................................................................220  9.5.2.2  Monoclonal Antibodies ..............................................................................................222  9.5.2.3  Purified Proteins........................................................................................................223  9.5.3  Performance of Top Players .............................................................................................224  9.5.4  Market Forecasts (2010-2015)..........................................................................................225  9.6  Indonesia ..................................................................................................................................227  9.6.1  Market Performance (2005-2009).....................................................................................227  9.6.2  Market Segmentation by Class .........................................................................................227  9.6.2.1  Recombinant Proteins...............................................................................................228  9.6.2.2  Monoclonal Antibodies ..............................................................................................230  9.6.2.3  Purified Proteins........................................................................................................232  9.6.3  Performance of Top Players .............................................................................................232  9.6.4  Market Forecasts (2010-2015)..........................................................................................234 
  • 8. © IMARC® List of Figures Figure 2-1: Global Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009.........................25  Figure 3-1: Complexity of Biopharmaceuticals ...........................................................................................27  Figure 3-2: Sources of Biopharmaceuticals................................................................................................28  Figure 4-1: Global: Share of Biopharmaceuticals & Small Molecule Drugs Among the Top Ten Selling Drugs (in %), 2000, 2009 & 2016................................................................................................................31  Figure 4-2: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be Equivalent to Originator Products ...............................................................................................................32  Figure 4-3: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different Production Process was Used ....................................................................................................................33  Figure 4-4: Transition Probabilities of Biopharmaceuticals & Small Molecule Drugs in Clinical Phases, (in %)................................................................................................................................................................34  Figure 4-5: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small Molecule Drugs, (in US$)............................................................................................................................36  Figure 4-6: Comparison of the Annual Cost of Therapy for Plaque Psoriasis Using Biopharmaceuticals and Small Molecule Drugs, (in US$)...........................................................................................................36  Figure 4-7: Emerging Biopharmaceutical Market Forecast, (in Million US$), 2009 & 2015 .......................40  Figure 4-8: Developed Biopharmaceutical Market Forecast, (in Million US$), 2009 & 2015 .....................40  Figure 4-9: Total Number of New Biopharmaceuticals Approved by the FDA (in Numbers), 1982-2009 ..41  Figure 4-10: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval, (in %), 1993-2004 ...................................................................................................................................................43  Figure 4-11: Global: Breakup of Small Molecule Drugs and Biopharmaceuticals in the Total Pharmaceutical Market & Phase III development, (%), 2009 .....................................................................43  Figure 4-12: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small Molecule Drugs, (in Million US$).................................................................................................................44  Figure 4-13: Research and Development Times Taken by Biopharmaceuticals to Reach the Market, (in Months), 1982-89,1990-94,1995-99, 2000-04, 2005-09.............................................................................45  Figure 4-14: Comparison of the Research & Development Times for Biopharmaceuticals & Small Molecule Drugs (in Months) ........................................................................................................................45  Figure 4-15: Germany: Volume Share of Branded and Biosimilar Products in the Erythropoietins Alpha Market, (in %), September 2007 & April 2010 ............................................................................................47  Figure 4-16: Current Medicare Payer Coverage for Monoclonal Antibodies..............................................47  Figure 4-17: Performance of Biotech Stocks During the Financial Crisis, (in %), Jan 2008 to Dec 2008..49  Figure 5-1: Global: Biopharmaceutical Market, (in Million US$), 2005-2009..............................................50  Figure 5-2: Global: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015...............................52  Figure 5-3: Global: Biopharmaceutical Market: Sales Share by Country, (in %), 2009..............................53  Figure 5-4: Global: Biopharmaceutical Market Forecast: Sales Share by Country, (in %), 2015...............55  Figure 5-5: Global: Biopharmaceutical Market: Sales Share by Indication, (in %), 2009...........................56  Figure 5-6: Global: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009....................57  Figure 5-7: Global: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ........................57  Figure 5-8: Global: Biopharmaceutical Market Forecast: Sales by Class, (in Million US$), 2010-2015.....58  Figure 5-9: Global: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2010-2015.........58  Figure 5-10: Global: Recombinant Proteins Market, (in Million US$), 2005-2009......................................59  Figure 5-11: Global: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 .........................61  Figure 5-12: Global: Recombinant Proteins Market Forecast, (in Million US$), 2010-2015.......................61  Figure 5-13: Global: Recombinant Proteins Market Forecast: Sales Share by Class, (in %), 2015 ..........63  Figure 5-14: Global: Monoclonal Antibodies Market, (in Million US$), 2005-2009.....................................64  Figure 5-15: Global: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009.........................65  Figure 5-16: Global: Monoclonal Antibodies Market Forecast, (in Million US$), 2010-2015......................69  Figure 5-17: Global: Monoclonal Antibodies Market Forecast: Sales Share by Class, (in %), 2015..........70  Figure 5-18: Global: Purified Proteins Market, (in Million US$), 2005-2009...............................................71  Figure 5-19: Global: Purified Proteins Market: Sales Share by Class, (in %), 2009...................................71  Figure 5-20: Global: Purified Proteins Market Forecast, (in Million US$), 2010-2015................................72  Figure 5-21: Global: Purified Proteins Market Forecast: Sales Share by Class, (in %), 2015 ...................73  Figure 5-22: Global Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009.......................75  Figure 6-1: US: Biopharmaceutical Market, (in Million US$), 2005-2009...................................................77 
  • 9. © IMARC® Figure 6-2: US: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009.........................78  Figure 6-3: US: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 .............................78  Figure 6-4: US: Recombinant Proteins Market, (in Million US$), 2005-2009 .............................................79  Figure 6-5: US: Recombinant Proteins Market: Sales Share by Class, (in %), 2009.................................80  Figure 6-6: US: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ............................................80  Figure 6-7: US: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ................................81  Figure 6-8: US: Purified Proteins Market, (in Million US$), 2005-2009 ......................................................82  Figure 6-9: US: Purified Proteins Market: Sales Share by Class, (in %), 2009..........................................83  Figure 6-10: US: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ...........................84  Figure 6-11: US: Biopharmaceutical Market Forecast, (in Million US$), 2009-2015..................................85  Figure 6-12: US: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015......................85  Figure 6-13: Canada: Biopharmaceutical Market, (in Million US$), 2005-2009 .........................................86  Figure 6-14: Canada: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ...............86  Figure 6-15: Canada: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009....................87  Figure 6-16: Canada: Recombinant Proteins Market, (in Million US$), 2005-2009....................................87  Figure 6-17: Canada: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 .......................89  Figure 6-18: Canada: Monoclonal Antibodies Market, (in Million US$), 2005-2009...................................89  Figure 6-19: Canada: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ......................90  Figure 6-20: Canada: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009....................92  Figure 6-21: Canada: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 ..........................93  Figure 6-22: Canada: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015..............93  Figure 7-1: Mexico: Biopharmaceutical Market, (in Million US$), 2005-2009.............................................94  Figure 7-2: Mexico: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009...................95  Figure 7-3: Mexico: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009.......................95  Figure 7-4: Mexico: Recombinant Proteins Market, (in Million US$), 2005-2009.......................................95  Figure 7-5: Mexico: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ..........................97  Figure 7-6: Mexico: Monoclonal Antibodies Market, (in Million US$), 2005-2009......................................97  Figure 7-7: Mexico: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009..........................98  Figure 7-8: Mexico: Purified Proteins Market, (in Million US$), 2005-2009................................................99  Figure 7-9: Mexico: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009.....................100  Figure 7-10: Mexico: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015..........................101  Figure 7-11: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 .............101  Figure 7-12: Brazil: Biopharmaceutical Market, (in Million US$), 2005-2009...........................................102  Figure 7-13: Brazil: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009.................102  Figure 7-14: Brazil: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 .....................103  Figure 7-15: Brazil: Recombinant Proteins Market, (in Million US$), 2005-2009 .....................................103  Figure 7-16: Brazil: Recombinant Proteins Market: Sales Share by Class, (in %), 2009.........................105  Figure 7-17: Brazil: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ....................................105  Figure 7-18: Brazil: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ........................106  Figure 7-19: Brazil: Purified Proteins Market, (in Million US$), 2005-2009 ..............................................107  Figure 7-20: Brazil: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 .....................109  Figure 7-21: Brazil: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015............................109  Figure 7-22: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015................110  Figure 7-23: Argentina: Biopharmaceutical Market, (in Million US$), 2005-2009.....................................111  Figure 7-24: Argentina: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009...........111  Figure 7-25: Argentina: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009...............112  Figure 7-26: Argentina: Recombinant Proteins Market, (in Million US$), 2005-2009...............................112  Figure 7-27: Argentina: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ..................114  Figure 7-28: Argentina: Monoclonal Antibodies Market, (in Million US$), 2005-2009..............................114  Figure 7-29: Argentina: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009..................115  Figure 7-30: Argentina: Purified Proteins Market, (in Million US$), 2005-2009........................................116  Figure 7-31: Argentina: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009...............117  Figure 7-32: Argentina: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 .....................118  Figure 7-33: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 .........118  Figure 8-1: Germany: Biopharmaceutical Market, (in Million US$), 2005-2009 .......................................119  Figure 8-2: Germany: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 .............120  Figure 8-3: Germany: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009..................120  Figure 8-4: Germany: Recombinant Proteins Market, (in Million US$), 2005-2009 .................................120 
  • 10. © IMARC® Figure 8-5: Germany: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 .....................122  Figure 8-6: Germany: Monoclonal Antibodies Market, (in Million US$), 2005-2009.................................122  Figure 8-7: Germany: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ....................123  Figure 8-8: Germany: Purified Proteins Market, (in Million US$), 2005-2009 ..........................................124  Figure 8-9: Germany: Purified Proteins Market: Sales Share by Class, (in %), 2009 ..............................125  Figure 8-10: Germany: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ...............126  Figure 8-11: Germany: Biopharmaceutical Market Forecast, (in Million US$), 2009-2015 ......................127  Figure 8-12: Germany: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015..........127  Figure 8-13: France: Biopharmaceutical Market, (in Million US$), 2005-2009.........................................128  Figure 8-14: France: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009...............128  Figure 8-15: France: Biopharmaceutical Market: Sales Share By Class, (in %), 2005-2009...................129  Figure 8-16: France: Recombinant Proteins Market, (in Million US$), 2005-2009...................................129  Figure 8-17: France: Recombinant Proteins Market: Sales Share by Class, (in %), 2009.......................131  Figure 8-18: France: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ..................................131  Figure 8-19: France: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009......................132  Figure 8-20: France: Purified Proteins Market, (in Million US$), 2005-2009............................................133  Figure 8-21: France: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009...................134  Figure 8-22: France: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015..........................135  Figure 8-23: France: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 .............135  Figure 8-24: Italy: Biopharmaceutical Market, (in Million US$), 2005-2009 .............................................136  Figure 8-25: Italy: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ...................136  Figure 8-26: Italy: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009........................137  Figure 8-27: Italy: Recombinant Proteins Market, (in Million US$), 2005-2009........................................137  Figure 8-28: Italy: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ...........................139  Figure 8-29: Italy: Monoclonal Antibodies Market, (in Million US$), 2005-2009.......................................139  Figure 8-30: Italy: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ..........................140  Figure 8-31: Italy: Purified Proteins Market, (in Million US$), 2005-2009.................................................141  Figure 8-32: Italy: Biopharmaceutical Market: Sales Share of top players, (in %), 2009 .........................142  Figure 8-33: Italy: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 ..............................143  Figure 8-34: Italy: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015..................144  Figure 8-35: Spain: Biopharmaceutical Market, (in Million US$), 2005-2009...........................................145  Figure 8-36: Spain: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009.................145  Figure 8-37: Spain: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 .....................146  Figure 8-38: Spain: Recombinant Proteins Market, (in Million US$), 2005-2009.....................................146  Figure 8-39: Spain: Recombinant Proteins Market: Sales Share by Class, (in %), 2009.........................148  Figure 8-40: Spain: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ....................................148  Figure 8-41: Spain: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009........................149  Figure 8-42: Spain: Purified Proteins Market, (in Million US$), 2005-2009..............................................150  Figure 8-43: Spain: Purified Proteins Market: Sales Share by Class, (in %), 2009..................................151  Figure 8-44: Spain: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009.....................152  Figure 8-45: Spain: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015............................153  Figure 8-46: Spain: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 ...............153  Figure 8-47: UK: Biopharmaceutical Market, (in Million US$), 2005-2009...............................................154  Figure 8-48: UK: Biopharmaceutical Market, Sales by Class, (in Million US$), 2005-2009.....................155  Figure 8-49: UK: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 .........................155  Figure 8-50: UK: Recombinant Proteins Market, (in Million US$), 2005-2009 .........................................156  Figure 8-51: UK: Recombinant Proteins Market: Sales Share by Class, (in %), 2009.............................157  Figure 8-52: UK: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ........................................158  Figure 8-53: UK: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ............................159  Figure 8-54: UK: Purified Proteins Market, (in Million US$), 2005-2009 ..................................................159  Figure 8-55: UK: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 .........................161  Figure 8-56: UK: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015................................162  Figure 8-57: UK: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015....................162  Figure 8-58: Russia: Biopharmaceutical Market, (in Million US$), 2005-2009.........................................163  Figure 8-59: Russia: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009...............164  Figure 8-60: Russia: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ...................164  Figure 8-61: Russia: Recombinant Proteins Market, (in Million US$), 2005-2009 ...................................165  Figure 8-62: Russia: Recombinant Proteins Market: Sales Share by Class, (in %), 2009.......................166 
  • 11. © IMARC® Figure 8-63: Russia: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ..................................167  Figure 8-64: Russia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ......................168  Figure 8-65: Russia: Purified Proteins Market, (in Million US$), 2005-2009 ............................................168  Figure 8-66: Russia: Purified Proteins Market: Sales Share by Class, (in %), 2009................................169  Figure 8-67: Russia: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ...................171  Figure 8-68: Russia: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015..........................171  Figure 8-69: Russia: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015..............172  Figure 8-70: Turkey: Biopharmaceutical Market, (in Million US$), 2005-2009.........................................173  Figure 8-71: Turkey: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009...............174  Figure 8-72: Turkey: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ...................174  Figure 8-73: Turkey: Recombinant Proteins Market, (in Million US$), 2005-2009 ...................................175  Figure 8-74: Turkey: Recombinant Proteins Market: Sales Share by Class, (in %), 2009.......................176  Figure 8-75: Turkey: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ......................178  Figure 8-76: Turkey: Purified Proteins Market, (in Million US$), 2005-2009 ............................................178  Figure 8-77: Turkey: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ...................180  Figure 8-78: Turkey: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015..........................180  Figure 8-79: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015..............181  Figure 9-1: Japan: Biopharmaceutical Market, (in Million US$), 2005-2009 ............................................183  Figure 9-2: Japan: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ..................183  Figure 9-3: Japan: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009.......................184  Figure 9-4: Japan: Recombinant Proteins Market, (in Million US$), 2005-2009 ......................................184  Figure 9-5: Japan: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ..........................186  Figure 9-6: Japan: Monoclonal Antibodies Market, (in Million US$), 2005-2009......................................186  Figure 9-7: Japan: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 .........................187  Figure 9-8: Japan: Purified Proteins Market, (in Million US$), 2005-2009 ...............................................188  Figure 9-9: Japan: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ......................190  Figure 9-10: Japan: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 ...........................191  Figure 9-11: Japan: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015...............191  Figure 9-12: China: Biopharmaceutical Market, (in Million US$), 2005-2009...........................................192  Figure 9-13: China: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009.................193  Figure 9-14: China: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009.....................193  Figure 9-15: China: Recombinant Proteins Market, (in Million US$), 2005-2009.....................................194  Figure 9-16: China: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ........................195  Figure 9-17: China: Monoclonal Antibodies Market, (in Million US$), 2005-2009....................................196  Figure 9-18: China: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009........................197  Figure 9-19: China: Purified Proteins Market, (in Million US$), 2005-2009..............................................197  Figure 9-20: China: Purified Proteins Market: Sales Share by Class, (in %), 2009..................................198  Figure 9-21: China: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009.....................200  Figure 9-22: China: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 ...........................200  Figure 9-23: China: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 ...............201  Figure 9-24: Australia: Biopharmaceutical Market, (in Million US$), 2005-2009......................................202  Figure 9-25: Australia: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009............202  Figure 9-26: Australia: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ................203  Figure 9-27: Australia: Recombinant Proteins Market, (in Million US$), 2005-2009 ................................203  Figure 9-28: Australia: Recombinant Proteins Market: Sales Share by Class, (in %), 2009....................205  Figure 9-29: Australia: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ...............................205  Figure 9-30: Australia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009...................206  Figure 9-31: Australia: Purified Proteins Market, (in Million US$), 2005-2009 .........................................207  Figure 9-32: Australia: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ................208  Figure 9-33: Australia: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015.......................209  Figure 9-34: Australia: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015...........209  Figure 9-35: South Korea: Biopharmaceutical Market, (in Million US$), 2005-2009................................210  Figure 9-36: South Korea: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009......211  Figure 9-37: South Korea: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ..........211  Figure 9-38: South Korea: Recombinant Proteins Market, (in Million US$), 2005-2009 ..........................212  Figure 9-39: South Korea: Recombinant Proteins Market: Sales Share by Class, (in %), 2009..............213  Figure 9-40: South Korea: Monoclonal Antibodies Market, (in Million US$), 2005-2009 .........................214  Figure 9-41: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009.............215 
  • 12. © IMARC® Figure 9-42: South Korea: Purified Proteins Market, (in Million US$), 2005-2009 ...................................215  Figure 9-43: South Korea: Purified Proteins Market: Sales Share by Class, (in %), 2009.......................216  Figure 9-44: South Korea: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ..........217  Figure 9-45: South Korea: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015.................218  Figure 9-46: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015.....218  Figure 9-47: India: Biopharmaceutical Market, (in Million US$), 2005-2009 ............................................219  Figure 9-48: India: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ..................220  Figure 9-49: India: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009.......................220  Figure 9-50: India: Recombinant Proteins Market, (in Million US$), 2005-2009 ......................................221  Figure 9-51: India: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ..........................222  Figure 9-52: India: Monoclonal Antibodies Market, (in Million US$), 2005-2009......................................222  Figure 9-53: India: Purified Proteins Market, (in Million US$), 2005-2009 ...............................................223  Figure 9-54: India: Purified Proteins Market: Sales Share by Class, (in %), 2009 ...................................224  Figure 9-55: India: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ......................225  Figure 9-56: India: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 .............................226  Figure 9-57: India: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015.................226  Figure 9-58: Indonesia: Biopharmaceutical Market, (in Million US$), 2005-2009 ....................................227  Figure 9-59: Indonesia: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ..........228  Figure 9-60: Indonesia: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009...............228  Figure 9-61: Indonesia: Recombinant Proteins Market, (in Million US$), 2005-2009...............................229  Figure 9-62: Indonesia: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ..................230  Figure 9-63: Indonesia: Monoclonal Antibodies Market, (in Million US$), 2005-2009..............................230  Figure 9-64: Indonesia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 .................231  Figure 9-65: Indonesia: Purified Proteins Market, (in Million US$), 2005-2009........................................232  Figure 9-66: Indonesia: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009...............233  Figure 9-67: Indonesia: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 .....................234  Figure 9-68: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015.........234 
  • 13. © IMARC® List of Tables Table 1-1: Global: Biopharmaceutical Market: Definition & Segmentation.................................................19  Table 2-1: Global: Biopharmaceutical Market: SWOT Analysis .................................................................21  Table 2-2: Global: Recombinant Proteins Market Forecast: Sales by Class, (in Million US$), 2009 & 2015 ....................................................................................................................................................................22  Table 2-3: Global: Monoclonal Antibodies Market Forecast: Sales by Class, (in Million US$), 2009 & 2015 ....................................................................................................................................................................23  Table 2-4: Global: Purified Proteins Market Forecast: Sales by Class, (in Million US$), 2009 & 2015......23  Table 2-5: Global: Biopharmaceutical Market Forecast: Sales by Region, (in Million US$), 2009 & 2015 24  Table 3-1: Differences Between Small Molecule Drugs & Biopharmaceuticals .........................................26  Table 3-2: Complexity of Manufacturing Process Involved with Biopharmaceuticals & Small Molecule Drugs...........................................................................................................................................................28  Table 4-1: Global: Top Ten Selling Drugs (Based on Origin), 2000 ...........................................................30  Table 4-2: Global: Top Ten Selling Drugs (Based on Origin), 2009 ...........................................................30  Table 4-3: Global: Top Ten Selling Drugs Forecast (Based on Origin), 2016............................................31  Table 4-4: Mode of Administration of Popular Biotech Drugs.....................................................................35  Table 4-5: FDA: Total Number of Biopharmaceutical Approvals in 2009...................................................42  Table 4-6: US and European Statistics of Branded Biopharmaceutical Products Facing Biosimilar Threat, (in Million US$), 2009..................................................................................................................................46  Table 5-1: Global: Biopharmaceutical Market: Sales by Country (in Million US$), 2005-2009 ..................53  Table 5-2: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million US$), 2010-2015 ...55  Table 5-3: Global: Biopharmaceutical Market: Sales by Indication, (in Billion US$), 2009 ........................56  Table 5-4: Global: Contribution of Various Classes to Total Biopharmaceutical Growth, (in Million US$), 2009-2015 ...................................................................................................................................................59  Table 5-5: Global: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009...............60  Table 5-6: Global: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ...................60  Table 5-7: Global: Recombinant Proteins Market Forecast: Sales by Class, (in %), 2010-2015...............62  Table 5-8: Global: Recombinant Proteins Market Forecast: Sales Share by Class, (in %), 2010-2015 ....62  Table 5-9: Global: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 ..............64  Table 5-10: Global: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009.................64  Table 5-11: Global: Humanized Monoclonal Antibodies Market: Sales of Marketed Products, (in 000’ US$), 2009 ..................................................................................................................................................65  Table 5-12: Global: Chimeric Monoclonal Antibodies Market: Sales of Marketed Products, (in 000’ US$), 2009 ............................................................................................................................................................66  Table 5-13: Global: Fully Human Monoclonal Antibodies Market: Sales of Marketed Products, (in 000’ US$), 2009 ..................................................................................................................................................66  Table 5-14: Global: Murine Monoclonal Antibodies Market: Sales of Marketed Products, (in 000’ US$), 2009 ............................................................................................................................................................66  Table 5-15: Global: Murine Monoclonal Antibodies in Phase-III Development .........................................67  Table 5-16: Global: Chmeric Monoclonal Antibodies in Phase-III Development........................................68  Table 5-17: Global: Humanized Monoclonal Antibodies in Phase-III Development ...................................68  Table 5-18: Global: Fully Human Monoclonal Antibodies in Phase-III Development .................................68  Table 5-19: Global: Immunotoxins in Phase-III Development ...................................................................69  Table 5-20: Global: Monoclonal Antibodies Market Forecast: Sales by Class, (in Million US$), 2010-2015 ....................................................................................................................................................................69  Table 5-21: Global: Monoclonal Antibodies Market Forecast: Sales Share by Class, (in %), 2010-2015..70  Table 5-22: Global: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009......................71  Table 5-23: Global: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 ..........................71  Table 5-24: Global: Purified Proteins Market Forecast: Sales by Class, (in Million US$), 2010-2015.......72  Table 5-25: Global: Purified Proteins Market Forecast: Sales Share by Class, (in %), 2010-2015 ...........72  Table 5-26: Global: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 .........74  Table 5-27: Global: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009..............74  Table 5-28: Global: Biopharmaceutical Market; Sales Forecast of Top Biopharmaceuticals, (in Million US$), 2009 & 2016......................................................................................................................................76  Table 6-1: US: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ....................79  Table 6-2: US: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009.........................79 
  • 14. © IMARC® Table 6-3: US: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009....................81  Table 6-4: US: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009........................81  Table 6-5: US: Purified Proteins Market: Sales by Class, 2005-2009 ........................................................82  Table 6-6: US: Purified Proteins Market: Sales Share by Class, 2005-2009 .............................................82  Table 6-7: US: Biopharmaceutical Market: Sales of Top Players, (in US$), 2005-2009 ............................83  Table 6-8: US: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009 .....................84  Table 6-9: Canada: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009.............88  Table 6-10: Canada: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ...............88  Table 6-11: Canada: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009..........90  Table 6-12: Canada: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 ..............90  Table 6-13: Canada: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 .......91  Table 6-14: Canada: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009.............91  Table 7-1: Mexico: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009..............96  Table 7-2: Mexico: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ..................96  Table 7-3: Mexico: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 .............98  Table 7-4: Mexico: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009..................98  Table 7-5: Mexico: Purified Proteins Market: Sales by Class (in Million US$), 2005-2009........................99  Table 7-6: Mexico: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 .......100  Table 7-7: Mexico: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009.............100  Table 7-8: Brazil: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ..............104  Table 7-9: Brazil: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009...................104  Table 7-10: Brazil: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009............106  Table 7-11: Brazil: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009................106  Table 7-12: Brazil: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 .....................107  Table 7-13: Brazil: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009..........................107  Table 7-14: Brazil: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009.........108  Table 7-15: Brazil: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ..............108  Table 7-16: Argentina: Recombinant Proteins Market: Sales by Class, 2005-2009.................................113  Table 7-17: Argentina: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ..........113  Table 7-18: Argentina: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 .....115  Table 7-19: Argentina: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009..........115  Table 7-20: Argentina: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009...............116  Table 7-21: Argentina: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ..116  Table 7-22: Argentina: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009.......117  Table 8-1: Germany: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009.........121  Table 8-2: Germany: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009.............121  Table 8-3: Germany: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009........123  Table 8-4: Germany: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 ............123  Table 8-5: Germany: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009..................124  Table 8-6: Germany: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 ......................124  Table 8-7: Germany: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009.....125  Table 8-8: Germany: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009 .........126  Table 8-9: France: Recombinant Proteins Market: Sales by Class,(in Million US$), 2005-2009 .............130  Table 8-10: France: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009...............130  Table 8-11: France: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 .........132  Table 8-12: France: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009..............132  Table 8-13: France: Purified Proteins Market: Sales by Class, 2005-2009..............................................133  Table 8-14: France: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009.......134  Table 8-15: France: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009............134  Table 8-16: Italy: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009...............138  Table 8-17: Italy: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ...................138  Table 8-18: Italy: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009..............140  Table 8-19: Italy: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 ..................140  Table 8-20: Italy: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009........................141  Table 8-21: Italy: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 ............................141  Table 8-22: Italy: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ...........142  Table 8-23: Italy: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009.................142  Table 8-24: Spain: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ............147 
  • 15. © IMARC® Table 8-25: Spain: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009.................147  Table 8-26: Spain: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 ...........149  Table 8-27: Spain: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009................149  Table 8-28: Spain: Purified Proteins Market: Sales by Class, 2005-2009................................................150  Table 8-29: Spain: Purified Proteins Market: Sales Share by Class, 2005-2009 .....................................150  Table 8-30: Spain: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009.........151  Table 8-31: Spain: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009.............152  Table 8-32: UK: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ................156  Table 8-33: UK: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009.....................157  Table 8-34: UK: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009................158  Table 8-35: UK: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009....................158  Table 8-36: UK: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 .........................160  Table 8-37: UK: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009..............................160  Table 8-38: UK: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009.............161  Table 8-39: UK: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009 .................161  Table 8-40: Russia: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ..........165  Table 8-41: Russia: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009...............166  Table 8-42: Russia: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009..........167  Table 8-43: Russia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009..............167  Table 8-44: Russia: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ...................169  Table 8-45: Russia: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009........................169  Table 8-46: Russia: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009.......170  Table 8-47: Russia: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ............170  Table 8-48: Turkey: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ..........175  Table 8-49: Turkey: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009...............176  Table 8-50: Turkey: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009..........177  Table 8-51: Turkey: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009..............177  Table 8-52: Turkey: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ...................179  Table 8-53: Turkey: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009.......179  Table 8-54: Turkey: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ............179  Table 9-1: Japan: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009..............185  Table 9-2: Japan: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009..................185  Table 9-3: Japan: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009.............187  Table 9-4: Japan: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 .................187  Table 9-5: Japan: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009.......................188  Table 9-6: Japan: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 ...........................188  Table 9-7: Japan: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009..........189  Table 9-8: Japan: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ...............189  Table 9-9: China: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009..............194  Table 9-10: China: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ................195  Table 9-11: China: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 ...........196  Table 9-12: China: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009................196  Table 9-13: China: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009.....................198  Table 9-14: China: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 .........................198  Table 9-15: China: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ........199  Table 9-16: China: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009.............199  Table 9-17: Australia: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 .......204  Table 9-18: Australia: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009............204  Table 9-19: Australia: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009.......206  Table 9-20: Australia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009...........206  Table 9-21: Australia: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ................207  Table 9-22: Australia: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009....207  Table 9-23: Australia: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 .........208  Table 9-24: South Korea: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 .212  Table 9-25: South Korea: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009......213  Table 9-26: South Korea: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009.214  Table 9-27: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009.....214  Table 9-28: South Korea: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ..........216 
  • 16. © IMARC® Table 9-29: South Korea: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009...............216  Table 9-30: South Korea: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ..................................................................................................................................................................217  Table 9-31: South Korea: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009 ..217  Table 9-32: India: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009..............221  Table 9-33: India: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009..................221  Table 9-34: India: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009.............223  Table 9-35: India: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009.......................223  Table 9-36: India: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 ...........................223  Table 9-37: India: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009..........224  Table 9-38: India: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ...............225  Table 9-39: Indonesia: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009......229  Table 9-40: Indonesia: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ..........229  Table 9-41: Indonesia: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009.....231  Table 9-42: Indonesia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 .........231  Table 9-43: Indonesia: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009...............232  Table 9-44: Indonesia: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ..233  Table 9-45: Indonesia: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009........233 
  • 17. © IMARC® Prices and Order Information Single user license PDF Single user license CD ROM Single user license Hard Copy Multiple User License All Formats US$ 1,000 US$1,200 US$1,200 US$1,800 I would like to order the market Study “Global Biopharmaceutical Market Report (2010-2015)” Your Name: Job Title: Company: Email Id: Telephone Number: Address: Krishna Sharma International Market Research Analysis and Consulting Group 91-11-43095788 Sales@imarcgroup.com Kindly Complete Your Details Contact IMARC Group